Novonesis stock stands 1.27 percent below its 52-week high

Published on 10/15/2026 at 13:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Organic growth guidance rose to 7-8 percent from 5-7 percent. Novonesis stock costs EUR 61.39 on October 15, 2026 against a 52-week high of EUR 62.18.

Growth and deal context

MicroBioGen became part of Novonesis on October 1, 2026.
Organic growth guidance moved to 7-8 percent for fiscal year 2026.
Novonesis stock trades at EUR 61.39 at 1:40 p.m. CEST at Lang & Schwarz on October 15, 2026, 1.27 percent below its 52-week high.

Isometrische 3D-Grafik der Produktionskette industrieller Enzyme — Isometrische 3D-Grafik zeigt Wertschoepfungskette industrieller Enzyme von Novonesis (Novozymes), ISIN DK0060336014, vom Rohstoff zum Endprodukt, Illustration mit AI erstellt.

Novonesis (ISIN DK0060336014) was trading at EUR 61.39 at Lang & Schwarz on October 15, 2026 at 1:40 p.m. CEST. On October 2, 2026, BNP Paribas raised its price target from DKK 414.00 to DKK 420.00 while keeping a Neutral rating, according to IT Boltwise.

Stock sits near yearly high

The current euro quote is EUR 0.79 below the 52-week high of EUR 62.18 and remains within a EUR 45.15 to EUR 62.18 range. Those levels place the stock near the upper end of its recent trading history, while the lack of a dated Xetra comparison keeps the focus on the absolute market level.

What does the guidance mean?

Novonesis reported 8.00 percent organic sales growth in the first half of 2026 and an adjusted EBITDA margin of 37.70 percent. The company raised its full-year 2026 organic growth outlook to 7.00-8.00 percent from 5.00-7.00 percent, while retaining an adjusted EBITDA margin range of 37.00-38.00 percent, according to Novonesis and IT Boltwise. For investors, the combination of growth and margin delivery is more important than the target adjustment alone.

Three events shaped the stock

On September 28, 2026, Novonesis launched the first EUR 75.0 million tranche of a EUR 1.0 billion multiyear buyback, as reported by IT Boltwise. On October 1, 2026, Novonesis completed its acquisition of MicroBioGen, retaining access to yeast and research expertise, according to Markets Insider. On October 2, 2026, BNP Paribas lifted its target to DKK 420.00 from DKK 414.00, according to IT Boltwise.

Next dates bring fresh tests

The next reported earnings date is November 5, 2026, according to Simply Wall St. The first buyback tranche is scheduled to end by December 17, 2026, according to IT Boltwise.

Euro quote remains the anchor

Novonesis stock was trading at EUR 61.39 at Lang & Schwarz on October 15, 2026 at 1:40 p.m. CEST. The price was EUR 0.79 below the 52-week high of EUR 62.18, a distance of 1.27 percent.

The further course of trading is shown by the continuously updated real-time quote of Novonesis stock.